ArticleComplementary medicine research2026
Which Patients with Anxiety Symptoms Benefit Most from Treatment with <italic>Bryophyllum pinnatum</italic>? A Secondary Analysis of a Prospective, Single-Arm Study.
Article in Complementary medicine research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Introduction: Bryophyllum spp. preparations are frequently used in integrative settings. A recent study observed a reduction in anxiety symptoms among a heterogeneous group of psychiatric/psychosomatic patients after 2 weeks of treatment with Bryophyllum 50% chewable tablets. This secondary analysis aims to identify variables associated with a stronger reduction in anxiety symptoms.
methodsFifty-four patients with anxiety symptoms were recruited from the waiting list for inpatient care at the "Klinik Arlesheim," Department of Psychiatry and Psychosomatics, and treated with Bryophyllum 50% chewable tablets (3 × 2 per day; Weleda AG, Arlesheim, Switzerland). The primary outcome was a change in anxiety symptoms, measured by the Beck Anxiety Inventory (BAI) after 2 weeks of treatment relative to baseline (ΔBAI). Comparisons were made across subgroups using one-way ANOVA. Multivariate analyses (MVA) were conducted to assess the relative importance of various independent variables, including the depression scale (PHQ-9).
resultsBAI score decreased by an average of 5 points (from 27.4 ± 12.0 to 22.4 ± 12.1; p < 0.001, n = 54). ΔBAI decreased progressively across age quartiles and increased with baseline BAI scores (BAI
conclusionDue to the uncontrolled single-arm design, our findings are exploratory and do not permit causal inferences. Nevertheless, this explorative analysis suggests that younger age and more severe anxiety symptoms were associated with greater reductions in anxiety symptom burden during treatment with Bryophyllum 50% chewable tablets. </p>.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.